Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utidelone Capsule vs Injection in HER-2 Negative Advanced Breast Cancer
NCT07684456Phase 3Not yet recruiting
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
- Start
- Aug 2026
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
A Phase 3 trial of utidelone in breast cancer, sponsored by Beijing Biostar Pharmaceuticals Co., Ltd.. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
utidelone
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07684456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07684456.